A one-year study on the pharmacodynamic profile of interferon-beta1a in MS.
Neurology
; 58(9): 1409-11, 2002 May 14.
Article
em En
| MEDLINE
| ID: mdl-12011292
ABSTRACT
Interferon (IFN)-beta1a induction of neopterin and beta2-microglobulin (beta2-MG) were evaluated over 1 year in patients with MS. Neopterin and beta2-MG levels peaked 24 to 48 hours after weekly injections of IFNbeta1a over the entire study period. Predose levels of neopterin decreased significantly, consistent with a long-term decrease in IFNgamma expression and macrophage activation during IFNbeta-1a treatment. Predose levels of beta2-MG increased, the significance of which is as yet unclear.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Microglobulina beta-2
/
Interferon beta
/
Neopterina
/
Esclerose Múltipla Recidivante-Remitente
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2002
Tipo de documento:
Article